3 January 2020 in Science Advances
We clarify that DNA damage triggers autophagy by CHK2-FOXK axis, and misregulation of this pathway leads to chemoresistance.
11 April 2022 in Hepatology
Background and Aims: Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown. Approach and Results: Proteomic analysis in nonaggregated hepatocytes and aggregates containing HcPCs from a diethylnitrosamine‐induced HCC mouse model was screened using a quantitative mass spectrometry–based approach to elucidate the dysregulated proteins in HcPCs. The heterotrimeric G stimulating protein α subunit (GαS) protein level was significantly increased in liver cancer progenitor HcPCs, which promotes their response to oncogenic and proinflammatory cytokine IL‐6 and drives premalignant HcPCs to fully established HCC. Mechanistically, GαS was located at the membrane inside of hepatocytes and acetylated at K28 by acetyltransferase lysine acetyltransferase 7 (KAT7) under IL‐6 in HcPCs, causing the acyl protein thioesterase 1–mediated depalmitoylation of GαS and its cytoplasmic translocation, which were determined by GαS K28A mimicking deacetylation or K28Q mimicking acetylation mutant mice and hepatic Kat7 knockout mouse. Then, cytoplasmic acetylated GαS associated with signal transducer and activator of transcription 3 (STAT3) to impede its interaction with suppressor of cytokine signaling 3, thus promoting in a feedforward manner STAT3 phosphorylation and the response to IL‐6 in HcPCs. Clinically, GαS, especially K28‐acetylated GαS, was determined to be increased in human hepatic premalignant dysplastic nodules and positively correlated with the enhanced STAT3 phosphorylation, which were in accordance with the data obtained in mouse models. Conclusions: Malignant progression of HcPCs requires increased K28‐acetylated and cytoplasm‐translocated GαS, causing enhanced response to IL‐6 and driving premalignant HcPCs to fully established HCC, which provides mechanistic insight and a potential target for preventing hepatocarcinogenesis.
27 May 2024 in Advanced Science
DNA damage plays a significant role in the tumorigenesis and progression of the disease. Abnormal DNA repair affects the therapy and prognosis of cancer. In this study, it is demonstrated that the deubiquitinase USP25 promotes non‐homologous end joining (NHEJ), which in turn contributes to chemoresistance in cancer. It is shown that USP25 deubiquitinates SHLD2 at the K64 site, which enhances its binding with REV7 and promotes NHEJ. Furthermore, USP25 deficiency impairs NHEJ‐mediated DNA repair and reduces class switch recombination (CSR) in USP25‐deficient mice. USP25 is overexpressed in a subset of colon cancers. Depletion of USP25 sensitizes colon cancer cells to IR, 5‐Fu, and cisplatin. TRIM25 is also identified, an E3 ligase, as the enzyme responsible for degrading USP25. Downregulation of TRIM25 leads to an increase in USP25 levels, which in turn induces chemoresistance in colon cancer cells. Finally, a peptide that disrupts the USP25‐SHLD2 interaction is successfully identified, impairing NHEJ and increasing sensitivity to chemotherapy in PDX model. Overall, these findings reveal USP25 as a critical effector of SHLD2 in regulating the NHEJ repair pathway and suggest its potential as a therapeutic target for cancer therapy.
25 March 2026 in EMBO Reports
Hepatocellular carcinoma (HCC) is a primary liver malignancy with high rates of morbidity and mortality, yet effective treatment options remain limited. Accumulating evidence indicates that large tumour suppressor kinase 1 (LATS1), a core kinase in the Hippo pathway, mediates the phosphorylation of downstream YAP/TAZ, thereby suppressing HCC progression. Although LATS1 protein stability has been reported to be modulated by ubiquitination, the specific mechanism controlling LATS1 kinase activity remains unknown. Here, we identify USP25 as a deubiquitinase that regulates LATS1 activity, independent of LATS1 protein stability. We demonstrated that USP25 is overexpressed in HCC and that USP25 depletion significantly suppresses HCC cell and tumour growth. Mechanistically, USP25 catalyses the removal of K63-linked ubiquitin at K688 of LATS1, which disrupts LATS1-MOB1 complex formation and promotes YAP-mediated transcriptional activation. Furthermore, we successfully developed a cell-penetrating peptide that disrupts the USP25-LATS1 interaction, which increases p-YAP expression and synergizes with chemotherapy in xenograft and patient-derived organoid and xenograft models. Collectively, our findings reveal a mechanism through which USP25 regulates LATS1 activity and provide a potential therapeutic strategy for HCC treatment.
22 September 2026 in Nucleic Acids Research
Xeroderma pigmentosum group A (XPA) serves as a core nucleotide excision repair (NER) factor essential for the repair process triggered by UV irradiation. Lactylation, a newly identified post-translational modification, plays a key role in tumorigenesis and cancer progression. Herein, we discovered that XPA was lactylated in the DNA-binding domain by the acyl-transferase KAT5. In addition, UV irradiation promoted XPA lactylation, thereby increasing the chromatin recruitment of XPA and NER. However, the mutation of XPA to a lactylation-deficient form impeded XPA chromatin recruitment under UV irradiation, impaired NER, and rendered cancer cells hypersensitive to UV irradiation. Our data demonstrate that the lactylation of XPA plays a crucial role in NER and reveals the link between metabolic reprogramming and DNA damage repair induced by UV irradiation.